Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
Claims 1, 38, 43, 52, 54-55, 68-70, 73, 77, 81, 87, 89, 92-99 are pending.
Claims 92-99 are new.
Claim 98 is withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 12/30/2025. Claim 98 is a pyrimidinyl group not a substituted pyrimidinyl group.
Claims 70, 73, 77, and 81 were previously withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse.
Claims 1, 38, 43, 52, 54-55, 68-69, 87, 89, 92-97, and 99 are pending.
A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 12/4/2025 has been entered.
Species Under Examination
Applicant previously elected Group I, and species of (i) the target antigen BCMA, (ii) L-D of Formula (D)
PNG
media_image1.png
138
289
media_image1.png
Greyscale
and a single species of:
PNG
media_image2.png
449
607
media_image2.png
Greyscale
in the reply filed on 2/5/2025 is acknowledged.
Claims 1, 38, 43, 52, 54-55, 68-69, 87, 89, 92, 94-97, and 99 read on the elected species and are under examination.
The elected species of:
PNG
media_image3.png
439
594
media_image3.png
Greyscale
only has non-statutory double patenting rejections.
The Examiner previously rejoined two additional species for examination that are now outside of the amended claimed subject matter.
The next Examiner elected species is:
PNG
media_image4.png
174
385
media_image4.png
Greyscale
wherein A is
PNG
media_image5.png
23
311
media_image5.png
Greyscale
, wherein * is attached to D and D is
PNG
media_image6.png
257
222
media_image6.png
Greyscale
, which is named compound 2 in the instant specification.
The Examiner elected species is present in claims 1, 43, 52, 54-55, 68-69, 87, 93, 95-97, and 99.
Objections and Rejections Withdrawn
The objections to claim 23 is withdrawn in view of claim amendment.
The rejections to claims 5, 14, 23, 30, 32, 34, 55, and 68 under 35 USC §112(b) are withdrawn in view of claim amendment.
The rejections to claims 1, 4-5, 12-14, 68-69, and 87 under 35 USC §102 are withdrawn in view of claim amendment.
The rejections to claims 1, 4-5, 12-14, 23, 25-26, 32, 34, 39, 43, 52, 54-55, 68-69, 87, and 89 under 35 USC §103 are withdrawn in view of claim amendment.
The rejections to claims 1, 4-5, 12-14, 23, 25-26, 30, 32, 34, 37-39, 43, 52, 54-55, 68-69, 87, and 89 under Nonstatutory Double Patenting are withdrawn in view of claim amendment.
New Rejections Necessitated by Amendment
Regarding the species of
PNG
media_image4.png
174
385
media_image4.png
Greyscale
wherein A is
PNG
media_image5.png
23
311
media_image5.png
Greyscale
, wherein * is attached to D and D is
PNG
media_image6.png
257
222
media_image6.png
Greyscale
, which is named compound 2 in the instant specification.
Claim Rejections - 35 USC § 112(b)
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 52, 89, and 92-93 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Regarding instant claim 52, (15) references “Table A” in the claim. MPEP 2173.05 (s) indicates where possible, claims are to be complete in themselves. Incorporation by reference to a specific figure or table "is permitted only in exceptional circumstances where there is no practical way to define the invention in words and where it is more concise to incorporate by reference than duplicating a drawing or table into the claim. Incorporation by reference is a necessity doctrine, not for applicant’s convenience." Ex parte Fressola, 27 USPQ2d 1608, 1609 (Bd. Pat. App. & Inter. 1993) (citations omitted).
Regarding instant claims 52 and 93-94 the structure of D or R03 is indefinite because the claimed structure is recited to “comprise” the drawn structure. It is unclear whether further chemical moieties can be included within the drawn structure. Further, regarding instant claim 52, while only (2) is present in the elected species, “comprises” is present in the further selectable options of (1) to (14).
Regarding instant claim 89, the claim lists compounds and claims a salt thereof followed by “(e.g., pharmaceutically acceptable salt thereof)”. "e.g." is an abbreviation for the Latin phrase exempli gratia, meaning "for example". It is not clear whether the recitation of pharmaceutically acceptable salt thereof is a preferred example—and therefore not limiting—or further limitations of the scope of the claim. Further, the content of the parentheses does not define or equate to the preceding terminology and thus is exemplary claim language which is unclear.
Claim Rejections - 35 USC § 112(a)
Claims 1, 43, 52, 54-55, 68-69, 87, 93, 95-97, and 99 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention.
Regarding instant claim 1, the Applicant does not have possession of antibody-drug conjugates that include payload P2 that are effective antibody drug conjugates as seen in Tables 28-29 or Figs 6-7. Payload P2 is compound C2 and the IC50 cytotoxic response in cancer cells is about 10 µM, which is the least effective Mcl-1 inhibitor of the 14 inhibitors tested in the instant specification in Table 23 on page 568. Further, the site of attachment of the Mcl-1 inhibitor to the linker is not specifically defined in the claim outside of “wherein one of R03 or R012 groups is covalently attached to the linkers”. Thus, multiple different conjugation points are possible that have not been tested for activity. Instant claims 43, 52, 54-55, 68-69, 87, 93, 95-96, 97, and 99 are dependent on claim 1 and further contain the elected species.
Scope of the claimed genus
Regarding claims 1, 38, 43, 52, 54-55, 68-69, 87, 89, and 92-99, an antibody-drug conjugate is claimed of formula Ab-(L-D), wherein the a) linker and b) Mcl-1 inhibitor drug under examination are: a)
PNG
media_image7.png
455
755
media_image7.png
Greyscale
; and b)
PNG
media_image6.png
257
222
media_image6.png
Greyscale
, wherein the drug is attached to the linker at the R03 or R012 position, and wherein p is an integer from 1 to 16.
Summary of Species disclosed in the original specification
The instant specification tests antibody drug conjugates wherein the Mcl-1 inhibitors tested are payloads P1-P2 and C1-C14 and P15-P17, wherein P1 has the structure of compound 1 and P2 has the structure of C2.
The structure of compounds C1-C14 are:
PNG
media_image8.png
231
212
media_image8.png
Greyscale
;
PNG
media_image9.png
255
225
media_image9.png
Greyscale
;
PNG
media_image10.png
233
231
media_image10.png
Greyscale
;
PNG
media_image11.png
146
268
media_image11.png
Greyscale
;
PNG
media_image12.png
251
236
media_image12.png
Greyscale
;
PNG
media_image13.png
233
210
media_image13.png
Greyscale
;
PNG
media_image14.png
203
209
media_image14.png
Greyscale
;
PNG
media_image15.png
202
200
media_image15.png
Greyscale
;
PNG
media_image16.png
234
219
media_image16.png
Greyscale
;
PNG
media_image17.png
242
245
media_image17.png
Greyscale
;
PNG
media_image18.png
255
212
media_image18.png
Greyscale
;
PNG
media_image19.png
212
239
media_image19.png
Greyscale
;
PNG
media_image20.png
282
273
media_image20.png
Greyscale
; and
PNG
media_image21.png
214
186
media_image21.png
Greyscale
, respectively (specification page 532-550).
The structure of compounds P15-P17 are:
PNG
media_image22.png
209
309
media_image22.png
Greyscale
;
PNG
media_image23.png
236
290
media_image23.png
Greyscale
;
PNG
media_image24.png
271
295
media_image24.png
Greyscale
Specification pages 551-552.
Table 23 shows inhibition of Mcl-1 by Fluorescence Polarization (FP} and cancer cell cytotoxicity IC50 values, wherein compound C2 has a cancer cell cytotoxicity IC50 value of about 10 µM and is the highest value of all the compounds tested.
PNG
media_image25.png
286
725
media_image25.png
Greyscale
Antibody-drug conjugates comprising compound C2 in Tables 28-29 or Figs 6-7 do not show activity against cancer cells.
Linker L24, which is labeled as (14) in instant claim 1, was active when conjugated to compounds C1 and C6-C7, and anti-CD33 and anti-HER2 antibodies (Fig 8A, 9A and 19B). Compounds C1 and C6-C7 have cancer cell IC50 values from about 2 to 3 nM, which is about 3,000 times more potent against cancer cells when compared to compound C2.
The Applicant does not have possession of an effective antibody drug conjugate comprising compound C2. Only compounds C1, C3-C14 and P15-P17 showed activity in antibody-drug conjugates.
Further, the site of attachment of the Mcl-1 inhibitor to the linker is not specifically defined in the claim outside of “wherein one of R03 or R012 groups is covalently attached to the linkers”. Thus, multiple different conjugation points are possible that have not been tested for activity. Thus, conjugation to the Mcl-1 inhibitor and release of the ADC payload is not guaranteed.
State of the Relevant Art
EP2886545 (Kotschy A et al. IDS reference) taught the Mcl-1 inhibitor of Example 30 with the structure:
PNG
media_image26.png
335
552
media_image26.png
Greyscale
(page 115) was an effective Mcl-1 inhibitor and cytotoxic to cancer cells (page 262, Table 1). Kotschy taught the compounds may be linked to monoclonal antibodies or fragments thereof (page 17, paragraph 45).
Li taught antibody-drug conjugates (ADC) comprise targeting antibodies armed with potent small-molecule payloads (Li F et al. Cancer Res (2016) 76 (9): 2710–2719, abstract). Li taught membrane permeability and the ability of the released payload to diffuse through the tumor are required for bystander killing and it is important to evaluate engineered payload for their membrane permeability and bystander killing (page 2717, left column, second to last paragraph). Li taught intertumoral release of membrane permeable MMAE released from cAC10-vcMMAE kills both CD30+ cells and CD30− cells in vivo, whereas another auristatin payload that is impermeable, MMAF, lacked such capacity (page 2717, left column, second to last paragraph).
Dal Corso A et al. (Journal of Controlled Release 2017 264 211-218) taught that the Val-Cit linker, connecting the F16 antibody to PNU159682, is cleaved by proteases that are intracellular (e.g., cathepsin B), but that are also released in the extracellular space upon tumor cell death, wherein the acidic tumor microenvironment may facilitate the activation of these hydrolytic enzymes, triggering drug release by proteolysis (page 217, left column, second paragraph). Dal Corso taught hydrophilic or charged drugs released in the extracellular environment fail to subsequently cross the tumor cell membrane (page 217, left column, third paragraph). Thus, ADCs comprising Val-Cit linkers can be cleaved extracellularly to release payloads wherein cell permeability is important for activity.
One of skill in the art would reasonably conclude that applicant was not in possession of antibody-drug conjugates that include payload P2 that are effective antibody drug conjugates. Mcl-1 variants that were shown to be effective include Mcl-1 inhibitors with the structure of C1, C3-C14 and P15-P17, wherein the Mcl-1 inhibitor connection point is shown in the Examples in the specification.
Summary
A genus of species is not present in the instant specification that would demonstrate a structure activity relationship would be known for Mcl-1 inhibitors other than Mcl-1 inhibitors with the structure of C1, C3-C14 and P15-P17 with a defined Mcl-1 inhibitor connection point as shown in the Examples in the specification. Applicant does not have possession of antibody-drug conjugates that include payload P2 that are effective antibody drug conjugates as seen in Tables 28-29 or Figs 6-7, wherein payload P2 is compound C2. No linkers within the application show the compound is effective as an antibody-drug conjugate.
Response to Arguments
Independent claim 1 has been amended.
Applicant argues the structure of payload P2 is depicted below:
PNG
media_image27.png
192
177
media_image27.png
Greyscale
The present application provides that P2 is a potent Mcl-1 inhibitor (IC50 is about 2.6 nM). See the specification as filed, Table 23. It is also active in inhibiting NCI-H929 cancer cells (its cytotoxicity against NCI-H929 cells is about 8.51 μM). Id. Furthermore, the present application has demonstrated that an active Mcl-1 inhibitor, when conjugated with an antibody, its resulting ADC would be active against cancer cells. See, for example, Ab B-L9-C9 in Figure 10A which is a potent ADC (IC50 is 7.55 nM) against NCI-H929 cells in the MTT assay. In view of teachings and suggestions of the present application, a person skilled in the art would have a reasonable expectation that P2, being an active Mcl-1 inhibitor, when conjugated with an antibody, its resulting ADC would be active against cancer cells as well.
Applicant argues the present claim scope is commensurate with the unexpected data demonstrated in present application
In response, Applicant's arguments filed 12/4/2025 have been fully considered
but they are not persuasive. In response to the amended claim 1, the updated rejection is above. Regarding instant claim 1, the Applicant does not have possession of antibody-drug conjugates that include payload P2 that are effective antibody drug conjugates as seen in Tables 28-29 or Figs 6-7. Payload P2 is compound C2 and the IC50 cytotoxic response in cancer cells is about 10 µM, which is the least effective Mcl-1 inhibitor of the 14 inhibitors tested in the instant specification in Table 23 on page 568. Ab B-L9-C9 in Figure 10A does not contain compound 2. The written description rejection is above.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Regarding the elected species of
PNG
media_image2.png
449
607
media_image2.png
Greyscale
and the compounds of instant claim 89.
Claim 89 is provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-3, 8, 12-13, 18, 22-23, 25-26, 37-38, 47-51, 61-62, and 66-69 of copending Application No. 17/613,020. Although the claims at issue are not identical, they are not patentably distinct from each other because copending claim 38 claims
PNG
media_image28.png
213
178
media_image28.png
Greyscale
which is an identical structure to the claimed structure in instant claim 89.
This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented.
Response to Arguments
While Applicants disagree with the merit of the rejection, Applicants respectfully request the provisional double patenting rejection be held in abeyance until allowable subject matter are identified.
In response, Applicant's arguments filed 12/4/2025 have been fully considered
but they are not persuasive. Applicant requests that the double patenting rejection over co-pending application 17/613,020 be held in abeyance. A request to hold a rejection in abeyance is not a proper response to a rejection. Rather, a request to hold a matter in abeyance may only be made in response to an OBJECTION or REQUIREMENTS AS TO FORM (see 37 CFR 1.111(b) and MPEP §714.02). The double patenting rejection is above.
Claims 1, 38, 43, 52, 54-55, 68-69, 87, 92, 94-97, and 99 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-3, 8, 12-13, 18, 22-23, 25-26, 37-38, 47-51, 61-62, and 66-69 of copending Application No. 17/613,020 in view of WO 2019025983 (Kinneer K et al. reference of record) and Staben LR et al. (ACS Med. Chem. Lett. 2017, 8, 1037−1041 reference of record).
‘020 taught an antibody drug conjugate, wherein Ab is an anti-CD74 antibody, p is an integer from 1 to 16 and D is a Mcl-1 inhibitor in copending claim 1, wherein the structure was:
PNG
media_image29.png
462
602
media_image29.png
Greyscale
in copending claim 22, the Mcl-1 inhibitor D was
PNG
media_image30.png
181
154
media_image30.png
Greyscale
in copending claim 38, and a pharmaceutical composition comprising the antibody-drug conjugate and a pharmaceutically acceptable carrier in copending claim 49.
The claims of ‘020 did not teach: 1) the antibody target as BCMA and a single embodiment of the elected species, but this is obvious in view of Staben and Kinneer.
Staben taught a quaternary ammonium salt peptide linker that is amenable to the stable connection and traceless release of tertiary amines for antibody drug conjugates (page 1038, left to right column, bridging paragraph). Staben taught that traceless release avoids potential loss of drug potency (page 1038, left to right column, bridging paragraph). Staben taught an effective pharmaceutical composition with a vehicle carrier of an anti-CD22 antibody drug conjugate with a maleimide- valine-citrulline- self-immolative group linked to a toxic payload via a tertiary amine that was effective against cancer in vivo (Fig. 4A-C)
PNG
media_image31.png
166
525
media_image31.png
Greyscale
Staben taught the antibody drug conjugate in a liquid composition of 20 mM histidine acetate and sucrose as a carrier (Supp page 3, Supp Materials and Methods, preparation of conjugates). Staben taught the antibody had a drug to antibody ratio of 2 (page 1039).
Kinneer taught BCMA protein has been detected on the surface of plasma cells from multiple myeloma patients and has been investigated as a possible therapeutic target for multiple myeloma (page 1 paragraph 3). Kinneer taught an anti-BCMA antibody drug conjugate of 15B2GL-SG3249 which comprised a protease cleavable linker and self-immolative group (page 14, paragraph 43) and a monoclonal anti-BCMA antibody (page 23, paragraph 70), with a drug to antibody ratio of about 2 (page 27, Table 2), which effectively killed cancer cells in a pharmaceutical composition in vivo (Fig 4) with a pharmaceutically acceptable carrier (page 17, paragraph 51). Kinneer taught conjugation of the anti-BCMA antibody drug conjugate comprising reacting an antibody with a cleavable linker joined to a payload under conditions that allow conjugation (page 25, paragraph 74).
Regarding instant claims 1, 38, 43, 52, 54-55, 68-69, 92, 94-97, and 99 it would have been obvious for a person having ordinary skill in the art to take the antibody drug conjugate of copending claim 1 wherein, p is an integer from 1 to 16 and D is a Mcl-1 inhibitor with the linker if copending claim 22 and the Mcl-1 inhibitor of copending claim 38 in a pharmaceutical composition with a carrier in copending claim 49 – and 1) connect the tertiary amine of the Mcl-1 inhibitor of copending claim 38 to the linker via the tertiary amine via a bond as taught by Staben, which would make A a bond; and 2) exchange the targeting antibody for the an anti-BCMA antibody 15B2GL of Kinneer.
This is obvious because: 1) the Mcl-1 inhibitor contains a tertiary amine that could be linked to the antibody drug conjugate of Staben in a traceless manner, wherein traceless release avoids potential loss of drug potency; and 2) 15B2GL was effective at targeting an antibody drug conjugate to cancer cells and killing them in vivo in a pharmaceutical composition with a pharmaceutically acceptable carrier in an antibody drug conjugate comprising a protease cleavable linker and self-immolative group.
This would produce a pharmaceutical composition with a pharmaceutical carrier and an anti-BCMA antibody drug conjugate of the elected species with the structure
PNG
media_image2.png
449
607
media_image2.png
Greyscale
,wherein the antibody is the BCMA targeting antibody 15B2GL which targets BCMA on cancer cells, and wherein the drug to antibody ratio is about 1 to 16. This meets the claim limitations of instant claims 1, 38, 43, 52, 54-55, 68-69, 89, 92, 94-97, and 99.
There is a reasonable expectation of success because: 1) attachment to an antibody with the effective val-cit- self-immolative benzene linked tertiary amine causes traceless release of the toxic payload which would be targeted to cancer cells; and 2) 15B2GL was effective at targeting an antibody drug conjugate to cancer cells and killing them in vivo in a pharmaceutical composition with a pharmaceutically acceptable carrier in an antibody drug conjugate comprising a protease cleavable linker and self-immolative benzene and would target the Mcl-1 inhibitor to BCMA expressing cancer cells.
Regarding instant claim 87, it would have been obvious for a person having ordinary skill in the art to use the method of Kinneer for conjugation of the anti-BCMA antibody drug conjugate comprising reacting an antibody with a cleavable linker joined to a payload under conditions that allow conjugation – and to connect the linker payload of ‘020, Staben, and Kinneer.
This is obvious with a reasonable expectation of success because the maleimide group of ‘020, Staben, and Kinneer that attaches the cleavable linker to the antibody is the same.
This is a provisional nonstatutory double patenting rejection.
Response to Arguments
While Applicants disagree with the merit of the rejection, Applicants respectfully request the provisional double patenting rejection be held in abeyance until allowable subject matter are identified.
In response, Applicant's arguments filed 12/4/2025 have been fully considered
but they are not persuasive. Applicant requests that the double patenting rejection over co-pending application 17/613,020 be held in abeyance. A request to hold a rejection in abeyance is not a proper response to a rejection. Rather, a request to hold a matter in abeyance may only be made in response to an OBJECTION or REQUIREMENTS AS TO FORM (see 37 CFR 1.111(b) and MPEP §714.02). The double patenting rejection is above.
Claims 1, 38, 43, 52, 54-55, 68-69, 87, 92, 94-97, and 99 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-3, 8, 12-13, 18, 22-23, 25-26, 37-38, 40-41, 43-51, 61-62, and 66-69 of copending Application No. 18/038,437 in view of WO 2019025983 (Kinneer K et al. reference of record) and Staben LR et al. (ACS Med. Chem. Lett. 2017, 8, 1037−1041 reference of record).
‘437 taught an antibody drug conjugate, wherein Ab is an anti-CD48 antibody, p is an integer from 1 to 16 and D is a Mcl-1 inhibitor in copending claim 1, wherein the structure was:
PNG
media_image29.png
462
602
media_image29.png
Greyscale
in copending claim 22, the Mcl-1 inhibitor D was
PNG
media_image30.png
181
154
media_image30.png
Greyscale
in copending claim 38, and a pharmaceutical composition comprising the antibody-drug conjugate and a pharmaceutically acceptable carrier in copending claim 43.
The claims of ‘437 did not teach: 1) the antibody target as BCMA and a single embodiment of the elected species, but this is obvious in view of Staben and Kinneer.
Staben taught a quaternary ammonium salt peptide linker that is amenable to the stable connection and traceless release of tertiary amines for antibody drug conjugates (page 1038, left to right column, bridging paragraph). Staben taught that traceless release avoids potential loss of drug potency (page 1038, left to right column, bridging paragraph). Staben taught an effective pharmaceutical composition with a vehicle carrier of an anti-CD22 antibody drug conjugate with a maleimide- valine-citrulline- self-immolative group linked to a toxic payload via a tertiary amine that was effective against cancer in vivo (Fig. 4A-C)
PNG
media_image31.png
166
525
media_image31.png
Greyscale
Staben taught the antibody drug conjugate in a liquid composition of 20 mM histidine acetate and sucrose as a carrier (Supp page 3, Supp Materials and Methods, preparation of conjugates). Staben taught the antibody had a drug to antibody ratio of 2 (page 1039).
Kinneer taught BCMA protein has been detected on the surface of plasma cells from multiple myeloma patients and has been investigated as a possible therapeutic target for multiple myeloma (page 1 paragraph 3). Kinneer taught an anti-BCMA antibody drug conjugate of 15B2GL-SG3249 which comprised a protease cleavable linker and self-immolative group (page 14, paragraph 43) and a monoclonal anti-BCMA antibody (page 23, paragraph 70), with a drug to antibody ratio of about 2 (page 27, Table 2), which effectively killed cancer cells in a pharmaceutical composition in vivo (Fig 4) with a pharmaceutically acceptable carrier (page 17, paragraph 51). Kinneer taught conjugation of the anti-BCMA antibody drug conjugate comprising reacting an antibody with a cleavable linker joined to a payload under conditions that allow conjugation (page 25, paragraph 74).
Regarding instant claims 1, 38, 43, 52, 54-55, 68-69, 92, 94-97, and 99, it would have been obvious for a person having ordinary skill in the art to take the antibody drug conjugate of copending claim 1 wherein, p is an integer from 1 to 16 and D is a Mcl-1 inhibitor with the linker if copending claim 22 and the Mcl-1 inhibitor of copending claim 38 in a pharmaceutical composition with a carrier in copending claim 43 – and 1) connect the tertiary amine of the Mcl-1 inhibitor of copending claim 38 to the linker via the tertiary amine via a bond as taught by Staben, which would make A a bond; and 2) exchange the targeting antibody for the an anti-BCMA antibody 15B2GL of Kinneer.
This is obvious because: 1) the Mcl-1 inhibitor contains a tertiary amine that could be linked to the antibody drug conjugate of Staben in a traceless manner, wherein traceless release avoids potential loss of drug potency; and 2) 15B2GL was effective at targeting an antibody drug conjugate to cancer cells and killing them in vivo in a pharmaceutical composition with a pharmaceutically acceptable carrier in an antibody drug conjugate comprising a protease cleavable linker and self-immolative group.
This would produce a pharmaceutical composition with a pharmaceutical carrier and an anti-BCMA antibody drug conjugate of the elected species with the structure
PNG
media_image2.png
449
607
media_image2.png
Greyscale
,wherein the antibody is the BCMA targeting antibody 15B2GL which targets BCMA on cancer cells, and wherein the drug to antibody ratio is about 1 to 16. This meets the claim limitations of instant claims 1, 38, 43, 52, 54-55, 68-69, 92, 94-97, and 99.
There is a reasonable expectation of success because: 1) attachment to an antibody with the effective val-cit- self-immolative benzene linked tertiary amine causes traceless release of the toxic payload which would be targeted to cancer cells; and 2) 15B2GL was effective at targeting an antibody drug conjugate to cancer cells and killing them in vivo in a pharmaceutical composition with a pharmaceutically acceptable carrier in an antibody drug conjugate comprising a protease cleavable linker and self-immolative benzene and would target the Mcl-1 inhibitor to BCMA expressing cancer cells.
Regarding instant claim 87, it would have been obvious for a person having ordinary skill in the art to use the method of Kinneer for conjugation of the anti-BCMA antibody drug conjugate comprising reacting an antibody with a cleavable linker joined to a payload under conditions that allow conjugation – and to connect the linker payload of ‘437, Staben, and Kinneer.
This is obvious with a reasonable expectation of success because the maleimide group of ‘437, Staben, and Kinneer that attaches the cleavable linker to the antibody is the same.
This is a provisional nonstatutory double patenting rejection.
Response to Arguments
Applicants disagree with the merit of the rejection, The instant application is a US national stage application of International Patent Application PCT/US2020/033615, filed on May 19, 2020. Therefore, the instant application has a patent term filing date of May 19, 2020. The '437 application is a US national stage application of International Patent Application PCT/US2021/060560, filed on November 23, 2021. Thus, the '437 application has a patent term filing date of November 23, 2021. Accordingly, the instant application has an earlier patent term filing date than the '437 application and the provisional double patent rejection should be withdrawn. See MPEP §804.Il(b)(i).
In response, Applicant's arguments filed 12/4/2025 have been fully considered
but they are not persuasive. Section 804 1.(b).i. of the M.P.E.P. sates if a provisional nonstatutory double patenting rejection is the only rejection remaining in an application having the earlier patent term filing date, the examiner should withdraw the rejection in the application having the earlier patent term filing date and permit that application to issue as a patent, thereby converting the provisional nonstatutory double patenting rejection in the other application into a nonstatutory double patenting rejection upon issuance of the patent. The instant application still has pending rejections.
Conclusion
No claims are allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to JOHN J SKOKO III whose telephone number is (571)272-1107. The examiner can normally be reached M-F 8:30 - 5:00.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Julie Z Wu can be reached at (571)272-5205. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/J.J.S./Examiner, Art Unit 1643
/Karen A. Canella/Primary Examiner, Art Unit 1643